Why Immatics N.V.’s (IMTX) Stock Is Down 5.22%
As of Friday, July 31, Immatics N.V.’s IMTX share price has dipped by 5.22%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Commentary & Analysis
Why Immatics N.V.’s (IMTX) Stock Is Up 5.02%
As of Tuesday, June 30, Immatics N.V.’s IMTX share price has surged by 5.02%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Immatics N.V.’s (IMTX) Stock Is Up 6.27%
As of Wednesday, June 17, Immatics N.V.’s IMTX share price has surged by 6.27%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Immatics N.V.’s (IMTX) Stock Is Down 10.05%
As of Tuesday, June 02, Immatics N.V.’s IMTX share price has dipped by 10.05%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Immatics N.V.’s (IMTX) Stock Is Down 7.90%
As of Tuesday, June 02, Immatics N.V.’s IMTX share price has dipped by 7.90%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,183.6 | $252.6 | 47% |
|
| Shares Out (Mil) | 155.2 | 52.3 | 72% |
|
| Institutional Ownership | 93.1% | 92.1% | 63% |
|
| Float (Mil) | 69.6 | 40.2 | 54% |
|
| Beta | 1.30 | 0.95 | 75% |
|
| Avg Daily Volume (000s) | 447 | 455 | 57% |
|
| Price Change (52-week) |
29.6% | 52.9% | 68% |
|
| Growth | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.2% | 13.6% | 51% |
|
| Net Income (5yr) | 2.2% | (9.9%) | 42% |
|
| EPS (5yr) | 18.9% | 16.0% | 66 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.3%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.483) | ($1.936) | ($1.895) | |
| Month Ago EPS | ($0.483) | ($1.942) | ($1.901) | |
| # Rev Up | 3 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.462) | ($1.753) | ($1.778) | |
| Year/Year Chg | (2.6%) | 2.4% | (9.2%) | |
| Financials | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $43 | $38 | 19% |
|
| Net Income (TTM) (Mil) | ($247) | ($43) | 5% |
|
| EPS (TTM) | ($1.968) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($213) | ($31) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $60 | $5 | 72% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $5 | 31% |
|
| Enterprise Value (Q1) (Mil) | $704 | $180 | 38% |
|
| Valuation | IMTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.25 | 2.56 | 55% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | IMTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (439.2%) | 63.8% | 0% |
|
| Net Margin | (574.9%) | (67.3%) | 1% |
|
| ROA | (36.7%) | (49.8%) | 15% |
|
| ROE | (44.1%) | (55.5%) | 16% |
|
| Liabilities to Assets | 16.1% | 30.3% | 10% |
|
| F-Score | 2 | 3 | na |
|
Immatics N.V. did not pass any screens on 7/31/2026.
